The Reye's Syndrome market is projected to reach CAGR 7.00% during the forecast period 2023-2032. Reye's SyndromeReye’s syndrome is a rare but serious illness that causes swelling in the liver and brain. The disease is most prevalent in the adolescent population who are recovering from a viral infection such as chickenpox and the flu. Few symptoms of the disease are inclusive of diarrhea, rapid breathing, seizures, and others. Application of aspirin in the treatment procedures of the viral infections is linked with the disease. Increasing prevalence of influenza and teenage population are the major drivers of the market growth. According to the 2015-2016 Influenza Burden Estimates of the Centers for Disease Control and Prevention, 9.2-35.6 million cases of influenza led to 140,000-710,000 hospitalizations and caused 12,000- 56,000 deaths annually since 2010. Moreover, according to the Child Trends, the number of children under 18 years of age is projected to increase from 74.1 million to 78.2 million by 2040. Additionally, increasing per capita healthcare expenditure and developing biotechnology & pharmaceutical sector within the developing economies across the world are estimated to fuel the reye’s syndrome market growth during the forecasted period. However, lack of awareness and limited treatment options may restrain the reye’s syndrome market growth during the forecast period.
Intended Audience
Figure 1:- Global Reye’s Syndrome Market share, by Region 
Sources: WHO, annual reports, press release, white paper, and company presentation
Key players in Global Reye’s Syndrome Market
General Electric Company (U.S.), Siemens Healthcare GmbH (Germany), CANON MEDICAL SYSTEMS CORPORATION (Japan), Koninklijke Philips N.V. (The Netherlands), NeuroLogica Corp. (U.S.), Sumitomo Corporation (Japan), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), AstraZeneca (U.K), Eli Lilly and Company (U.S.), Biocon (India), Ypsomed (Switzerland), BD (U.S.), ARGON MEDICAL (U.S.), and others.
Reye’s Syndrome Market Segmentation
The global Reye’s syndrome market is segmented on the basis of diagnosis, treatment and end users.
On the basis of the diagnosis, the market is segmented into tests, biopsy, imaging, and others. The test segment is sub-segmented into blood tests, urine tests, and others. The biopsy segment is sub-segmented into liver biopsy, skin biopsy, and others. The imaging segment is sub-segmented into computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and others.
On the basis of the treatment, the market is categorized into electrolytes and fluids, corticosteroids, ammonia detoxicants, insulin, and others.
On the basis of end users, the market is segmented into hospitals & clinics, research laboratories, diagnostic centers, and others.
Research Methodology 
Sources: WHO, annual reports, press release, white paper, and company presentation
Reye’s Syndrome Market Regional Analysis:
The Americas dominate the global Reye’s syndrome market due to the presence of a well-developed healthcare sector and rising healthcare expenditures. Moreover, the adolescent population which is susceptible to influenza is increasing, creating favorable backgrounds for the market growth. Additionally, the presence of the developed economies and market key players within the region are estimated to fuel the market growth during the forecast period.
Europe is the second largest market for Reye’s syndrome, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development are the major drives for the growth of the market within the region.
Asia Pacific is the fastest growing region for the market due to the presence of continuously developing economies like India and China which have developing biotechnology and pharmaceutical industries. Additionally, the presence of huge opportunities within the region fuels the growth. According to the Indian Brand Equity Foundation in 2016, India’s pharmaceuticals market is expected to reach USD 45 billion by 2020 from USD 18 billion in 2012.
On the other hand, the Middle East & Africa has the least share in the global Reye’s syndrome market due to the presence of poor economies, especially within the African region. A majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.
Reye’s Syndrome Market Highlights:
Frequently Asked Questions (FAQ) :
Global Rege’s Syndrome market is expected to expand at 7.00% CAGR from 2023 to 2032.
High prevalence of influenza among teens is the primary driver of the global Rege’s syndrome market.
Lack of awareness of the disease and limited treatment options are factors expected to impede the global Rege’s Syndrome market growth.
The Americas will dominate in the global Rege’s Syndrome market till 2023.
Merck & Co., Inc., Siemens Healthcare GmbH, Ypsomed, Eli Lilly and Company, BD, AstraZeneca, Biocon, Sumitomo Corporation, General Electric Company, Novartis AG, Koninklijke Philips N.V., Pfizer Inc., ARGON MEDICAL, NeuroLogica Corp., and CANON MEDICAL SYSTEMS CORPORATION are prominent players of the global Rege’s Syndrome market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
